Streamlining the dynamin epilepsy drug pipeline

简化动力癫痫药物管道

• 批准号: DP1095780
• 负责人: Prof Adam McCluskey
• 金额: $ 30.51万
• 依托单位: The University of Newcastle
• 依托单位国家: 澳大利亚
• 项目类别: Discovery Projects
• 财政年份: 2010
• 资助国家: 澳大利亚
• 起止时间: 2010-06-01 至 2013-06-30
• 项目状态: 已结题
• 来源: https://dataportal.arc.gov.au/RGS/Web/Grants/DP1095780
• 关键词: Streamlining; dynamin; epilepsy; drug; pipeline

Epilepsy affects up to one percent of Australia's population, yet one in three fail to respond to current medications. Our results will greatly impact on development of future epilepsy therapy. Identification of a new target for epileptic will allow better drug design to improve the potency of our lead drugs. This holds hope that new generation drugs will be more effective. The drugs are predicted to have fewer complications and side-effects. The outcome has the potential to vastly improve prospects for up to 200,000 Australians. Intellectual property (IP) retained in Australia will generate future biotechnology industry. The novel chemical biological approaches will facilitate training of future generations of Australian scientists.

癫痫病影响了多达澳大利亚人口的百分之一，但三分之一的人未能对当前的药物做出反应。 我们的结果将极大地影响未来癫痫疗法的发展。识别癫痫病的新靶标将允许更好的药物设计以提高铅药物的效力。 这希望新一代药物会更有效。预计这些药物的并发症和副作用较少。结果有可能大大提高多达20万澳大利亚人的前景。在澳大利亚保留的知识产权（IP）将产生未来的生物技术行业。新型的化学生物学方法将促进对澳大利亚科学家的后代培训。